BellRing Brands heads into its August 3 earnings report carrying a peculiar tension: short sellers have aggressively rebuilt positions after a catastrophic May print, yet the stock has rallied 34% over the past month and analysts are quietly raising their targets.
The short interest story is the dominant feature this week. Shorts have risen 46% over the past month, bringing the short interest to 14.6% of the free float — a meaningful rebuilding of bearish positioning that began in earnest around July 10, when shares on loan jumped from roughly 15.8 million to over 17.4 million in a single session. That's a sharp repricing of downside conviction. Yet the lending market tells a contradictory story: availability is genuinely loose at over 1,400% — meaning shares available to borrow dwarf current short interest by a factor of 14 — and cost to borrow has fallen nearly 20% over the week to a negligible 0.40%. Shorts are building, but they are doing so cheaply and with no friction. Options traders are not joining the bearish camp either. The put/call ratio of 0.22 is barely above its 20-day average and remains firmly in call-dominant territory, suggesting the options market is positioned for upside rather than downside protection ahead of the print.
Analysts have been moving targets higher despite the grim earnings history. Barclays raised its target to $14 from $13 this week, maintaining its Overweight rating. Stifel followed the same day, lifting to $15 from $14 with a Buy. UBS moved to $13.50 from $12 last week, though it held at Neutral. The direction of travel is clearly upward after the post-May carnage, when the stock fell 36% in a single day and continued dropping to a five-day loss of 45%. Targets across the Street were slashed from the mid-$20s to the low teens in early May — which makes the current cluster of $13–$15 targets look calibrated to a reset reality rather than recovery enthusiasm. The consensus mean of $13.88 sits only 10% above Tuesday's close of $12.66, a modest implied upside that keeps the risk-reward balanced rather than skewed. Valuation multiples have moved in line with the price recovery: the P/E has expanded by roughly two turns over the past month to 9.7x, and EV/EBITDA has crept to 7.8x. Factor scores are mixed — days-to-cover ranks in the 72nd percentile, pointing to meaningful cover risk if the stock moves sharply higher, but EPS momentum scores rank in the bottom quintile of the universe.
Institutional ownership adds some nuance. BlackRock added 3.1 million shares in Q2, bringing its stake to 9.7% — a notable accumulation. Millennium built a fresh position of 3.1 million shares as recently as late June. These are not passive flows; both additions were sizable relative to existing positions and came after the May collapse, suggesting at least some institutional buyers viewed the selloff as an overshoot. Diamond Hill also initiated a full position of 2.1 million shares. Against that backdrop, the insider picture is quiet: the only recent open-market buys were two small director purchases totaling around $72,000, with the last one in May at $9.24 — well below the current price.
The May earnings history is the unavoidable context. The last two results triggered one-day declines of 36% and 38% respectively, each followed by additional losses of 45% over five days. Whatever the mechanism — guidance cuts, a new CEO announcement, competitive pressure on Premier Protein — the market's reaction to bad news from BellRing has been severe. The August 3 print arrives with the stock 34% off its recent low but still well below the levels at which the CFO and CEO were selling shares last December near $31.
What to watch into August 3 is whether management frames the guidance reset as complete or flags further uncertainty — the sharp divergence between a rebuilding short base and institutional accumulation suggests the two camps have very different views on that question.
See the live data behind this article on ORTEX.
Open BRBR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
